Cortex Pharmaceuticals, Inc. Enters Into New License Agreement With The University of Illinois Granting Cortex Patent Rights To The Use Of Cannabinoids For The Treatment Of Sleep Related Breathing Disorders

Published: Jul 01, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

GLEN ROCK, N.J., July 1, 2014 (GLOBE NEWSWIRE) -- Cortex Pharmaceuticals, Inc. (OTC:CORX) ("Cortex" or the "Company"), a biopharmaceutical company currently engaged in the development of drugs for respiratory disorders, announced today that it has entered into a new license agreement with the University of Illinois that provides Cortex with exclusive rights to patents claiming the use of cannabinoids for the treatment of sleep related breathing disorders. Cortex is developing dronabinol (D9-tetrahydrocannabinol), a cannabinoid, for the treatment of obstructive sleep apnea (OSA), the most common form of sleep apnea.

Help employers find you! Check out all the jobs and post your resume.

Back to news